Global Latent TB Testing Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Latent TB Testing Market Size

• The global Latent TB Testing market was valued at USD 452.19 million in 2024 and is expected to reach USD 822.51 million by 2032
• During the forecast period of 2025 to 2032 the market is such asly to grow at a CAGR of 5.30%, primarily driven by factors such as the rising prevalence of latent TB, increasing awareness, and advancements in diagnostic technologies
• The market is being significantly bolstered by global initiatives aimed at tuberculosis (TB) elimination, which prioritize enhanced latent TB screening programs as a preventive measure to curb the progression to active TB cases

Latent TB Testing Market Analysis

• Latent TB Testing involves detecting dormant Mycobacterium tuberculosis bacteria in individuals without active TB symptoms. Common methods include the Tuberculin Skin Test (TST) and Interferon-Gamma Release Assays (IGRAs). These tests aim to identify latent infections and prevent progression to active TB
• Immunocompromised individuals, such as those with HIV/AIDS or undergoing organ transplants, are contributing to the rising demand for latent TB testing
• International organizations and governments are investing in TB control programs, promoting early detection and preventive measures for latent TB

• For instance, In April 2024, Revvity launched the Auto-Pure 2400 system to enhance the efficiency of latent TB testing, combining accuracy with streamlined workflows

• Globally, the latent TB testing market is poised for growth, driven by increasing awareness, technological advancements, and global efforts to combat tuberculosis effectively

Report Scope and Latent TB Testing Market Segmentation   

Latent TB Testing Market Trends

“Increased Screening in Low-Prevalence Countries”

• The latent TB testing market is projected to grow steadily, driven by the increasing prevalence of latent TB infections and advancements in diagnostic technologies such as IGRA tests and TSTs
• Immunocompromised individuals, such as those with HIV/AIDS or undergoing organ transplants, are contributing to the rising demand for latent TB testing

• For instance, in April 2024, Revvity launched the Auto-Pure 2400 system to enhance the efficiency of latent TB testing, combining accuracy with streamlined workflows

• International organizations and governments are investing in TB control programs, promoting early detection and preventive measures for latent TB
• The latent TB testing market is poised for growth, driven by increasing awareness, technological advancements, and global efforts to combat tuberculosis effectively

Latent TB Testing Market Dynamics

Driver

“Increased Incidence of latent TB Worldwide”

• Developing economies are increasing their healthcare budgets, enabling better access to diagnostic tools and facilities for latent TB testing. This creates a favorable environment for market expansion and innovation
• Many developing countries, such as India and South Africa, have a high prevalence of latent TB. This drives the demand for advanced testing solutions to address the growing public health challenge
• Governments and international organizations are actively funding TB control programs in developing regions. These initiatives promote awareness, early detection, and treatment of latent TB, boosting market growth
• The introduction of cost-effective and portable diagnostic technologies tailored for resource-limited settings is expanding the reach of latent TB testing in developing economies

For instance,

• In 2023, the Indian government launched a nationwide TB elimination program, which included funding for latent TB testing and treatment in high-risk populations. Another example is from 2024, when the Global Fund allocated significant resources to support TB testing initiatives in sub-Saharan Africa, improving access to diagnostics
• In 2025, the African Union launched a collaborative initiative to enhance latent TB testing across member nations. This program focused on deploying cost-effective diagnostic tools in rural and underserved areas, significantly improving access to testing and early detection

• Developing economies present significant growth opportunities for the Latent TB Testing Market, driven by rising healthcare investments, high disease burden, and supportive initiatives. These factors are paving the way for improved diagnostics and better disease management in resource-limited settings

Opportunity

“Opportunities for Growth in Developing Economies”

• AI-powered ophthalmic microscopes can enhance visualization, automate tasks, and improve diagnostic accuracy, enabling surgeons to make more informed decisions during surgical procedures
• AI algorithms can analyze real-time images and provide instant feedback on surgical procedures, helping surgeons identify potential complications, such as retinal tears or detachment
• Additionally, AI-powered microscopes can also assist in image analysis, enabling surgeons to review and compare images, track patient progress, and make more accurate diagnoses

For instance,

• In January 2025, according to an article published in the JMA Journal, AI algorithms, particularly those based on deep learning, can analyze retinal images with high accuracy, identifying and grading the severity of DR. These systems can quickly and efficiently process large volumes of images, reducing the burden on ophthalmologists and improving screening coverage. The ability of AI to detect early-stage DR and predict disease progression is crucial for timely intervention, which can significantly delay or even reverse the progression of the disease
• In November 2023, according to an article published in the National Library of Medicine, AI plays a pivotal role in optimizing postoperative visual outcomes, guiding the surgeon’s actions, and assessing the procedure’s effectiveness. The amount of data generated during the operation contributes to the indispensability of AI as a tool for enhancing patient outcomes

• The integration of AI in ophthalmic microscopes can also lead to improved patient outcomes, reduced recovery times, and enhanced quality of life. By leveraging AI-powered image analysis, surgeons can identify patients at risk for complications and take proactive measures to prevent them.

Restraint/Challenge

“Unfavorable Reimbursement Landscape”

• Many healthcare systems and insurance providers do not fully cover latent TB testing, making it expensive for patients and reducing accessibility, especially in low-income regions
• Patients often bear the financial burden of testing, which discourages routine screening and early detection, particularly in high-risk populations
• Reimbursement policies vary significantly across countries, with developed nations offering better coverage compared to developing regions, creating inequalities in access to testing
• Complex reimbursement procedures and delays in claim approvals further hinder the adoption of latent TB testing, affecting both patients and healthcare providers

For instance,

• In 2023, a study revealed that only 40% of latent TB testing costs were reimbursed in low-income countries, highlighting the financial barriers faced by patients. Another example is from 2024, where healthcare providers in the U.S. reported delays in reimbursement for IGRA tests, impacting their ability to offer timely diagnostics 
• In 2025, a global study revealed that the lack of comprehensive reimbursement policies for latent TB testing in low-income countries led to a 30% decline in testing rates. This highlighted the urgent need for policy reforms to improve access and affordability of diagnostic services

• The unfavorable reimbursement landscape poses a significant challenge to the Latent TB Testing Market, emphasizing the need for policy reforms and financial support to improve accessibility and encourage widespread testing

Latent TB Testing Market Scope

The market is segmented on the basis application, product type, technology, magnification type, end user, and distribution channel.

Latent TB Testing Market Regional Analysis

“North America is the Dominant Region in the Latent TB Testing Market”

• North America dominates the latent tb testing market, driven by stringent guidelines from CDC, WHO, and USPSTF for at-risk populations (such as healthcare workers, immigrants, immunocompromised individuals)
• Countries such as the U.K., Germany, and France are expanding TB screening programs, particularly for asylum seekers, refugees, and immunocompromised individuals
• Widespread adoption of IGRA tests over traditional TST, improving accuracy and reducing false positives
• The region is home to leading diagnostic companies and research institutions, driving innovation in latent TB testing technologies

“Asia-Pacific is Projected to Register the Highest Growth Rate”

•  Asia-Pacific is home to countries such as India and China, which have the highest TB burden globally. A significant portion of the population in these countries is affected by latent TB, increasing the demand for effective testing solutions to curb the progression to active TB
• Governments across the region are prioritizing healthcare infrastructure development and allocating funds toward TB detection and prevention. These investments are improving access to advanced diagnostic technologies in both urban and rural areas
• The introduction of affordable, portable, and efficient diagnostic tools tailored for low-resource settings has accelerated the adoption of latent TB testing solutions. These advancements are vital for addressing the needs of underserved populations in the region
• International organizations, including the World Health Organization (WHO) and the global fund, are implementing large-scale TB control programs in Asia-Pacific. These efforts aim to eliminate TB by promoting latent TB testing and facilitating early intervention strategies

Latent TB Testing Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• QIAGEN (Netherlands)
• SD Biosensor, INC. (South Korea)
• Boditech Med Inc. (South Korea)
• Revvity (U.S.)
• Lionex GmbH (Germany)
• invitros (South Korea)
• Beijing Wantai Biopharmaceutical Co., Ltd. (China)
• Serum Institute of India Pvt. Ltd. (India)
• Bioneovan Co., Ltd (China)
• Sanofi (France)
• ARKRAY, Inc. (Japan)
• Biopanda Reagents Ltd (U.K.)
• Endo, Inc. (U.S.)
• Zhi Fei Biological (China)
• bioMérieux (France)
• AID Autoimmun Diagnostika (Germany)

Latest Developments in Global Latent TB Testing Market

• In April 2024, Revvity (U.S.) launched the Auto-Pure 2400 liquid handler, developed by Allsheng, for use with the T-SPOT.TB test. This platform enables laboratories to streamline workflows, allowing latent TB testing to be conducted efficiently in mid-to-high-volume settings
• In March 2024, QIAGEN (Netherlands) partnered with the International Panel Physicians Association (IPPA) to support and educate panel physicians worldwide on the latest tuberculosis (TB) screening requirements. This collaboration emphasized the Interferon Gamma Release Assay (IGRA) requirements and their benefits for both patients and healthcare providers
• In February 2023, QIAGEN's (Netherlands) QuantiFERON-TB Gold Plus, a leading TB blood test, received the CE Mark under the European Union's 2017/746 In Vitro Diagnostic Medical Devices Regulation (IVDR). This certification replaced the earlier 98/79/EC In Vitro Diagnostic Directive (IVDD), ensuring compliance with more stringent regulatory standards for in vitro diagnostic devices
• In December 2022, bioMérieux (France) announced the CE-marking of VIDAS KUBE, a next-generation automated immunoassay system within the VIDAS assay range. This system includes the VIDAS TB-IGRA test for latent TB, offering significant benefits to clinical laboratories by delivering faster results, enhancing patient care, and ensuring consumer protection 

SKU-73701